Image

    067 BELCOMID: Belgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases

    Tom Hillary, An Van Laethem, Francisca Castelijns … Debabrata Bandyopadhyay
    Studysummary This study found no significant difference in the seroconversion rate of SARS-CoV2 IgG between patients with Immune Mediated Inflammatory diseases undergoing Targeted Immune-Modulating Therapies and those on conventional systemic treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jidonline.org →
    Discuss this study in the Community →